

Data Sharing Statement

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: Requests must be submitted in writing to the company's data sharing portal. More information can be found at <https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html>

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: These data will be shared with qualified scientific and medical researchers, upon researcher's request.

Types of analyses: Data will be provided as necessary for conducting legitimate research.

Mechanisms of data availability: Full details can be found at <https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html>

Any additional restrictions: For all new products or new indications approved in both the European Union and the United States after January 1, 2014, Merck KGaA, Darmstadt, Germany will share patient-level and study-level data after deidentification, as well as redacted study protocols and clinical study reports from clinical trials in patients. These data will be shared with qualified scientific and medical researchers, upon researcher's request, as necessary for conducting legitimate research. Such requests must be submitted in writing to the company's data sharing portal. More information can be found at <https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html>. Where Merck KGaA has a co-research, co-development or co-marketing/co-promotion agreement or where the product has been out-licensed, it is recognized that the responsibility for disclosure may be dependent on the agreement between parties. Under these circumstances, Merck KGaA will endeavour to gain agreement to share data in response to requests.